Barclays Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $185
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $141 to $185.
February 29, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on Sarepta Therapeutics and increased the price target from $141 to $185.
The upgrade in the price target by Barclays, a reputable financial institution, suggests a strong confidence in Sarepta Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100